- Report
- February 2026
- 250 Pages
Global
From €4063EUR$4,490USD£3,471GBP
- Report
- February 2026
- 250 Pages
Global
From €4063EUR$4,490USD£3,471GBP
- Report
- February 2026
- 250 Pages
Global
From €4063EUR$4,490USD£3,471GBP
- Report
- February 2026
- 250 Pages
Global
From €4063EUR$4,490USD£3,471GBP
- Report
- February 2026
- 250 Pages
Global
From €4063EUR$4,490USD£3,471GBP
- Report
- July 2026
- 181 Pages
Global
From €5294EUR$5,850USD£4,522GBP
- Report
- July 2026
- 285 Pages
Global
From €5294EUR$5,850USD£4,522GBP
- Report
- July 2026
- 180 Pages
Global
From €5294EUR$5,850USD£4,522GBP
- Report
- July 2026
- 282 Pages
Global
From €5294EUR$5,850USD£4,522GBP
- Report
- July 2026
- 289 Pages
Global
From €5294EUR$5,850USD£4,522GBP
- Report
- April 2026
- 235 Pages
Global
From €7230EUR$7,990USD£6,176GBP
- Report
- February 2026
- 200 Pages
Global
From €7230EUR$7,990USD£6,176GBP
- Report
- January 2026
- 220 Pages
Global
From €2262EUR$2,500USD£1,932GBP
- Report
- December 2025
- 200 Pages
Global
From €7194EUR$7,950USD£6,145GBP
- Report
- April 2026
- 981 Pages
Global
From €7230EUR$7,990USD£6,176GBP
- Report
- December 2025
- 200 Pages
Global
From €7194EUR$7,950USD£6,145GBP
- Report
- November 2025
- 200 Pages
Global
From €7194EUR$7,950USD£6,145GBP
- Report
- May 2026
- 150 Pages
Global
From €2442EUR$2,699USD£2,086GBP
- Report
- May 2026
- 150 Pages
Global
From €2524EUR$2,789USD£2,156GBP
- Report
- May 2026
- 150 Pages
Global
From €2524EUR$2,789USD£2,156GBP

Doxorubicin is an oncology drug used to treat a variety of cancers, including leukemia, lymphoma, and breast, ovarian, and bladder cancer. It is a type of anthracycline antibiotic, derived from Streptomyces peucetius, and works by interfering with the growth of cancer cells. It is administered intravenously, and is often used in combination with other drugs.
Doxorubicin is one of the most widely used chemotherapy drugs, and is often used in combination with other drugs to treat a variety of cancers. It is also used to treat Kaposi's sarcoma, a type of skin cancer. Side effects of doxorubicin include nausea, vomiting, hair loss, and an increased risk of infection.
The doxorubicin market is highly competitive, with many companies offering generic versions of the drug. Some of the major players in the market include Pfizer, Novartis, Merck, Bristol-Myers Squibb, and AstraZeneca. Show Less Read more